CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy

Jan Beck; Matthias Birtel; Daniel Reidenbach; Nadja Salomon; Mustafa Diken

doi:10.1080/21645515.2018.1504526

CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16^th Annual Meeting of the Association for Cancer Immunotherapy

Hum Vaccin Immunother. 2018;14(12):2864-2873. doi: 10.1080/21645515.2018.1504526. Epub 2018 Aug 29.

Authors

Jan Beck¹, Matthias Birtel¹, Daniel Reidenbach¹, Nadja Salomon¹, Mustafa Diken¹

Affiliation

¹ a TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH , Mainz , Germany.

Abstract

The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe's largest meeting series of its kind, took place in Mainz, Germany from 15-17 May, 2018. Cutting-edge advancements in cancer immunotherapy were discussed among more than 700 scientists under the motto "Pushing Frontiers in Cancer Immunotherapy". This meeting report is a summary of some of the CIMT 2018 highlights.

Keywords: CIMT; cancer immunotherapy; cellular therapy; checkpoint blockade; combination therapy; personalized therapy; tumor microenvironment; tumor vaccination.

MeSH terms

Animals
Congresses as Topic
Disease Models, Animal
Drug Therapy, Combination
Humans
Immunotherapy*
Neoplasms / therapy*
Tumor Microenvironment
Vaccination
Xenograft Model Antitumor Assays